Your patients with lupus nephritis can’t wait

Icon: Checkmark

Is BENLYSTA the right treatment choice for your patients right now?

Icon: Checklist

How to start a new patient on BENLYSTA

Learn More

GET TO KNOW BENLYSTA

SEE THE RESULTS OF BLISS-LN

Icon: Kidneys

Renal response

Icon: Renal Related Events

Renal-related events

Watch how BENLYSTA works

BENLYSTA is the first and only approved lupus treatment designed to target BLyS, an underlying cause of lupus1-3

Thumbnail: Video Coming Soon

BENLYSTA SELECTIVELY INHIBITS SOLUBLE BLyS, AN IMPORTANT FACTOR IN SLE1-3

How Benlysta Works
  1. In many patients with SLE, higher concentrations of BLyS promote increased B-cell survival, including the survival of autoreactive B cells.1
  2. BENLYSTA is a targeted human monoclonal antibody that binds to soluble BLyS, inhibiting its binding to B-cell receptors.2 BENLYSTA does not bind to B cells directly, but by binding to BlyS, BENLYSTA inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.
  3. By reducing the autoreactive B-cell population, BENLYSTA decreases the production of autoantibodies.

MEET A PATIENT WITH LUPUS NEPHRITIS WHO COULD BENEFIT FROM BENLYSTA

Icon: Publications

Learn about the data in patients with SLE

View the Trial Data

Now’s the time to treat lupus and lupus nephritis with BENLYSTA